Renata P. M.
- Country
- Poland
- Department
- Centrum Badań Klinicznych
Research Overview
- Randomized Phase 3 Study of Precemtabart Tocentecan With or Without Bevacizumab Versus Trifluridine/Tipiracil + Bevacizumab in Treated Metastatic Colorectal Cancer
- Phase 3 Randomized Study of PF-06821497 with Enzalutamide vs. Enzalutamide or Docetaxel in Metastatic Castration-Resistant Prostate Cancer Post-Abiraterone
- Phase 3 Randomized Double-Blind Study of PF-06821497 and Enzalutamide in Metastatic Castration-Resistant Prostate Cancer
Data & Insights
Has run more than one trial at 46 of 151 partner sites.
Specializations
Oncology Focus
This clinical investigator specializes in the treatment of metastatic castration-resistant prostate cancer, demonstrating particular expertise in advanced stages of the disease.
- Prostate Cancer Management
- Metastatic Disease Treatment
- Hormone-Resistant Cancer Therapy
Their research encompasses innovative therapeutic approaches for patients with progressive prostate cancer.
Novel Therapeutic Approaches
The investigator focuses on evaluating combination therapy strategies involving new investigational medicines alongside established treatments.
- Targeted Therapy Development
- Combined Treatment Modalities
- Treatment-Resistant Cases
Their work explores the potential of novel therapeutic agents in improving patient outcomes.
Treatment Innovation
This researcher specializes in investigating hormone therapy-resistant cases and developing alternative treatment pathways for advanced prostate cancer.
- Progressive Disease Management
- Novel Drug Assessment
- Treatment Sequencing
Their investigations focus on addressing unmet needs in advanced prostate cancer treatment.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.